Literature DB >> 20931389

The concept of multiple-target anti-miRNA antisense oligonucleotide technology.

Zhiguo Wang1.   

Abstract

The multiple-target AMO technology or MT-AMO technology is an innovative strategy, which confers on a single AMO fragment the capability of targeting multiple miRNAs. This modified AMO is single-stranded 2'-O-methyl-modified oligoribonucleotides carrying multiple AMO units, which are engineered into a single unit and are able to simultaneously silence multiple-target miRNAs or multiple miRNA seed families. Studies suggest that the MT-AMO is an improved approach for miRNA target finding and miRNA function validation; it not only enhances the effectiveness of targeting miRNAs but also confers diversity of actions. It has been successfully used to identify target genes and cellular function of several oncogenic miRNAs and of the muscle-specific miRNAs (Lu et al., Nucleic Acids Res 37:e24-e33, 2009). This novel strategy may find its broad application as a useful tool in miRNA research for exploring biological processes involving multiple miRNAs and multiple genes, and the potential as an miRNA therapy for human disease such as cancer and cardiac disorders. This technology was developed by my research laboratory in collaboration with Yang's group (Lu et al., Nucleic Acids Res 37:e24-e33, 2009), and it is similar but distinct from the miRNA Sponge technology developed by Sharp's laboratory in 2007 (Ebert et al., Nat Methods 4:721-726, 2007) and modified by Gentner et al. (Nat Methods 6:63-66, 2009).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20931389     DOI: 10.1007/978-1-60761-863-8_4

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  5 in total

Review 1.  Targeting microRNAs in pancreatic cancer: microplayers in the big game.

Authors:  Sheema Khan; Deepak Kumar; Meena Jaggi; Subhash C Chauhan
Journal:  Cancer Res       Date:  2013-11-07       Impact factor: 12.701

Review 2.  MicroRNA therapeutics in cardiovascular medicine.

Authors:  Thomas Thum
Journal:  EMBO Mol Med       Date:  2011-12-13       Impact factor: 12.137

3.  Does the linear Sry transcript function as a ceRNA for miR-138? The sense of antisense.

Authors:  Javier Tadeo Granados-Riveron; Guillermo Aquino-Jarquin
Journal:  F1000Res       Date:  2014-04-11

Review 4.  Inflammatory cells and their non-coding RNAs as targets for treating myocardial infarction.

Authors:  Mira Jung; Michael Dodsworth; Thomas Thum
Journal:  Basic Res Cardiol       Date:  2018-12-06       Impact factor: 17.165

Review 5.  Opportunities Offered by Graphene Nanoparticles for MicroRNAs Delivery for Amyotrophic Lateral Sclerosis Treatment.

Authors:  Benedetta Niccolini; Valentina Palmieri; Marco De Spirito; Massimiliano Papi
Journal:  Materials (Basel)       Date:  2021-12-24       Impact factor: 3.623

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.